IKT Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain...

Stats
Šios dienos apimtis	98 979.00
Vidutinė apimtis	103 828
Rinkos kapitalizacija	11.08M
EPS	$0 ( 2024-03-29 )
Kita pelno data	( $-0.790 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.480
ATR14	$0.0260 (1.52%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Werner Milton H.	Buy	45 000	Stock Option (right to buy)
2024-04-01	Lees-rolfe Garth	Buy	90 000	Stock Option (right to buy)
2024-04-01	Lees-rolfe Garth	Sell	5 834	Stock Option (right to buy)
2023-06-30	Berman Dennis N	Buy	6 667	Stock Option (right to buy)
2023-06-30	Dion Gisele	Buy	6 667	Stock Option (right to buy)

INSIDER POWER
96.54
Last 62 transactions
Buy: 1 923 769 \| Sell: 2 120 717

Tūris Koreliacija

Ilgas: -0.10 (neutral)

Trumpas: -0.36 (neutral)

Signal:(46.053) Neutral

Inhibikase Therapeutics, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SVOK	0.82

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Inhibikase Therapeutics, Koreliacija - Valiuta/Žaliavos

0.31
( neutral )

0.06
( neutral )

0.00
( neutral )

0.52
( weak )

-0.21
( neutral )

-0.12
( neutral )

Inhibikase Therapeutics, Finansinės ataskaitos

Annual	2023
Pajamos:	$260 500
Bruto pelnas:	$83 102.00 (31.90 %)
EPS:	$-3.57

FY	2023
Pajamos:	$260 500
Bruto pelnas:	$83 102.00 (31.90 %)
EPS:	$-3.57

FY	2022
Pajamos:	$123 440
Bruto pelnas:	$116 717 (94.55 %)
EPS:	$-4.26

FY	2021
Pajamos:	$3.10M
Bruto pelnas:	$3.10M (100.00 %)
EPS:	$-0.810

Financial Reports:

No articles found.

Inhibikase Therapeutics,

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.